ALK and non-small cell lung carcinoma: The results showed that the atezolizumab+bevacizumab+ carboplatin + paclitaxel (ABCP) arm prolonged PFS and OS in first-line nsq-NSCLC patients compared to the bevacizumab+ carboplatin + paclitaxel (BCP) arm, including the EGFR mutation and ALK translocation populations.